BioVie Analyst Price Targets

Wall Street analyst price targets and consensus rating for BioVie (BIVI).

Price Target Range — 2 Quarters

Analyst Consensus — 2 Analysts

2Buy

Consensus RatingOutperform# Analysts2Avg. Consensus PT$400Upside to Avg. PT+29975.2%

Rating Trend — Last 9 Months

Recent Analyst Actions

모든 평가 보기 →

Date	Firm	Analyst	Action	Rating Change	Price Target
Jul 1, 2024	ThinkEquity	Ashok Kumar	Initiate	Buy	$300
Nov 30, 2023	Oppenheimer	Jay Olson	PT Cut	Outperform	$1200→$500

Analyst Ratings News

PRO
ThinkEquity Initiates Coverage On BioVie with Buy Rating, Announces Price Target of $3

ThinkEquity analyst Ashok Kumar initiates coverage on BioVie (NASDAQ:BIVI) with a Buy rating and announces Price Target of $3.

Benzinga Newsdesk

PRO
Oppenheimer Maintains Outperform on BioVie, Lowers Price Target to $5

Oppenheimer analyst Jay Olson maintains BioVie (NASDAQ:BIVI) with a Outperform and lowers the price target from $12 to $5.

Benzinga Newsdesk

PRO
Cantor Fitzgerald Reiterates Overweight on BioVie, Maintains $11 Price Target

Cantor Fitzgerald analyst Charles Duncan reiterates BioVie (NASDAQ:BIVI) with a Overweight and maintains $11 price target.

Benzinga Newsdesk

PRO
Cantor Fitzgerald Reiterates Overweight on BioVie, Maintains $11 Price Target

Cantor Fitzgerald analyst Charles Duncan reiterates BioVie (NASDAQ:BIVI) with a Overweight and maintains $11 price target.

Benzinga Newsdesk

PRO
Cantor Fitzgerald Reiterates Overweight on BioVie, Maintains $11 Price Target

Cantor Fitzgerald analyst Charles Duncan reiterates BioVie (NASDAQ:BIVI) with a Overweight and maintains $11 price target.

Benzinga Newsdesk

PRO
Oppenheimer Reiterates Outperform on BioVie, Maintains $12 Price Target

Oppenheimer analyst Jay Olson reiterates BioVie (NASDAQ:BIVI) with a Outperform and maintains $12 price target.

Benzinga Newsdesk

BioVie Inc

뉴스

파트너 / 기고자

벤징가 글로벌

BioVie Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
ThinkEquity Initiates Coverage On BioVie with Buy Rating, Announces Price Target of $3

PRO
Oppenheimer Maintains Outperform on BioVie, Lowers Price Target to $5

PRO
Cantor Fitzgerald Reiterates Overweight on BioVie, Maintains $11 Price Target

PRO
Cantor Fitzgerald Reiterates Overweight on BioVie, Maintains $11 Price Target

PRO
Cantor Fitzgerald Reiterates Overweight on BioVie, Maintains $11 Price Target

PRO
Oppenheimer Reiterates Outperform on BioVie, Maintains $12 Price Target

People Also Watch

People Also Watch

BioVie Inc

뉴스

파트너 / 기고자

벤징가 글로벌

BioVie Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROThinkEquity Initiates Coverage On BioVie with Buy Rating, Announces Price Target of $3

PROOppenheimer Maintains Outperform on BioVie, Lowers Price Target to $5

PROCantor Fitzgerald Reiterates Overweight on BioVie, Maintains $11 Price Target

PROCantor Fitzgerald Reiterates Overweight on BioVie, Maintains $11 Price Target

PROCantor Fitzgerald Reiterates Overweight on BioVie, Maintains $11 Price Target

PROOppenheimer Reiterates Outperform on BioVie, Maintains $12 Price Target

People Also Watch

People Also Watch

PRO
ThinkEquity Initiates Coverage On BioVie with Buy Rating, Announces Price Target of $3

PRO
Oppenheimer Maintains Outperform on BioVie, Lowers Price Target to $5

PRO
Cantor Fitzgerald Reiterates Overweight on BioVie, Maintains $11 Price Target

PRO
Cantor Fitzgerald Reiterates Overweight on BioVie, Maintains $11 Price Target

PRO
Cantor Fitzgerald Reiterates Overweight on BioVie, Maintains $11 Price Target

PRO
Oppenheimer Reiterates Outperform on BioVie, Maintains $12 Price Target